Chemometec A/s · OMXCOP:CHEMM
Chemometec A/s — H1 2023/24 Earnings Presentation
14 slides from Chemometec A/s's earnings presentation, Feb 6, 2024
Slide 1: ChemoMetec A/S H1 2023/24 Interim Results Presentation
ChemoMetec A/S H1 2023/24 Interim results Presentation Webcast, February 6, 2024
Slide 2: Disclaimer
Certain statements in this presentation constitute forward- looking statements, i.e., statements related to future events and anticipated financial or operational performance. Forward- looking statements include, but are not limited to, statements addressing future results of operations, financial p
Slide 3: Today's speakers
Today’s speakers… Rasmus Kofoed Niels Høy Nielsen Group CEO Group CFO 3
Slide 4: ChemoMetec at a glance
ChemoMetec at a glance • Danish company, founded in 1997 • Globally one of the leading players within cell counting and analysis • Primary market: Cell and Gene Therapy • App. 170 FTEs worldwide • Full value chain (Global Sales, Marketing, Service, R&D, Quality & Production) • Operates a scalable bu
Slide 5: Highlights H1 2023/24
Highlights H1 2023/24 Challenging market still impacting results • Financial performance in line with expectations • Growth in sales of services and consumables, while sales of instruments continued declining significantly • Macro economic and market conditions still dampened funding and active tria
Slide 6: Still challenged funding situation but at a stabilized level
Still challenged funding situation but at a stabilized level Biotech industry, capital raised – EU & USA (USDb) Cell & Gene Therapy - Global Sources: EY analysis, (Capital IQ) and (Dow Jones VentureSource) Q1-Q3 = Realized; Q4 = Estimate Funding (USDb) Source: Alliance for Regenerative Medicine 22,7
Slide 7: Financial performance H1 2023/24
Financial performance H1 2023/24 Revenue EBITDA EBITDA-margin H1: DKK 199m (-17%) H1: +DKK 93m (-36%) H1: +47% H1 @ Constant Exchange rate: -14% H1 @ Constant Exchange rate: -32% H1 2022/23: 60.4% H1 2022/23: DKK 240.6m H1 2022/23: DKK 145.2m Profit Before Tax Cash Flow from operations Level of solv
Slide 8: Results for H1 2023/24 – Geographical segments
Results for H1 2023/24 – Geographical segments Revenue Share of revenue H1: DKK 115m NORTH AMERICA EUROPE REST OF WORLD NORTH AMERICA -18% FY 20222/23: +6% 58% 32% 10% EUROPE H1:DKK 64m -7% FY 2022/23: +1% REST OF H1: DKK 20m WORLD -37% FY 2022/23: -2% H1 2023/24 Interim results presentation
Slide 9: Results for H1 2023/24 – Product segments
Results for H1 2023/24 – Product segments INSTRUMENTS CONSUMABLES SERVICES Revenue (DKK) +61.8m Revenue (DKK) +89.6m Revenue (DKK) +46.0m Revenue growthI -43% Revenue growth +1% Revenue growth +12% (FY 2022/23: -17%) (FY 2022/23: +19%) (FY 2022/23: +39%) Share of revenue 31% Share of revenue 45% Sha
Slide 10: ESG highlights
ESG highlights Executing on ESG road map • Code of Conduct implemented successfully • Global Engagement survey rolled out and with an above benchmark engagement score of 78 (scale 1-100) • Dedicated internal ESG manager on-board Next steps • Implementation of Supplier Code of Conduct • Completing Do
Slide 11: Outlook 2023/24
Outlook 2023/24 • We still expect net revenue of DKK 400-435 million driven by price increases and XM40 instrument sales • The expected EBITDA is maintained in the range of DKK 200- 220m as we aspire a 50% EBITDA-margin 11 H1 2023/24 Interim results presentation
Slide 12: Management agenda
Management agenda 1. Successful launch of new innovation; XM40, XM30, Xcyto5 and NC-203 2. Margin focus 3. Reshaping ‘GROW’ strategy 4. Execute ESG roadmap 12 H1 2023/24 Interim results presentation
Slide 13: chemometec
chemometec
Slide 14: Thank you for your attention
Thank you for your attention 14